Sodium 9,10-dihydro-9,10-dioxoanthracene-2-sulphonate

Endpoint summary

Description of key information

In a valid oral toxicity study a dose of 2000 mg/kg bw of Luprintan TX 4493 (= Anthraquinone-2-sulfonic acid sodium salt) was tolerated without symptoms. None of the animals died. The LD50 was greater than 2000 mg/kg bw.

No studies for acute inhalation and dermal toxicity are available.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

comparable to guideline study with acceptable restrictions

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Principles of method if other than guideline:

Five male and five female Wistar rats received a single dose of Luprintan TX 4493 (= Anthraquinone-2-sulfonic acid sodium salt) per gavage. The animals were observed for mortality, clinical signs, weight gain for 14 days. A gross pathological examination of after sacrifice at the end of the study was performed.

GLP compliance:

not specified

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

Animals species: Rat / wistar / Dr. Thomae
Animal breeder: Dr. Thomae GmbH
Acclimatisation: At least 1 week
No. animals per dose: 5 male animals and 5 female animals
Type of cage: Stainless steel wire mesh cages, Type DK III
No. animals per cage: 5
Room temperature/ The animals were housed in fully air-conditioned rooms (20 - 24°C; relative humidity 30 - 70°C).
relative humidity
Day/night rhythm: 12 hours / 12 hours
Drinking water: Tap water ad libitum
Diet: Kliba Labordiaet 343
Animals weight: Animals of comparable weight (+/- 20% of the mean weight).

Route of administration:

oral: gavage

Vehicle:

other: 0.5% aqueous carboxymethyl cellulose

Details on oral exposure:

The animals were given no feed 16 hours before administration, but water was available ad libitum.

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5 male and 5 female animals per dose

Control animals:

no

Details on study design:

Signs and symptoms are recorded several times on the day of administration, at least once each workday. Check for moribund and dead animals twice each workday and once on holidays.
Withdrawal of food 16 hours before sacrifice; then necropsy with gross-pathological examination. Necropsy of all animals that die as early as possible.

Key result

Sex:

male/female

Dose descriptor:

discriminating dose

Effect level:

2 000 mg/kg bw

Remarks on result:

other: None of the animals died up to the end of the study

Mortality:

None

Clinical signs:

None

Body weight:

Males:
Begin of the test: 191 g
After 7 days: 262 g
After 13 days: 297 g
Females:
Begin of the test: 182 g
After 7 days: 211 g
After 13 days: 226 g

Gross pathology:

No abnormalities detected.

Interpretation of results:

GHS criteria not met

Conclusions:

A dose of 2000 mg/kg bw of Luprintan TX 4493 (= Anthraquinone-2-sulfonic acid sodium salt) was tolerated without symptoms. None of the animals died.
The LD50 is greater than 2000 mg/kg bw.

Executive summary:

Five male and five female Wistar rats received a single dose of Luprintan TX 4493 (= Anthraquinone-2-sulfonic acid sodium salt) per gavage. the animals were observed for mortality, clinical signs, weight gain for 14 days. A gross pathological examination of after sacrifice at the end of the study was performed. None of the animals died during the observation period. No clinical signs and no abnormalities were detected. therefore the LD50 is greater than 2000 mg/kg bw (discriminating dose).

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Quality of whole database:

Scientifically acceptable and suffient documented.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

In a valid oral toxicity study a dose of 2000 mg/kg bw of Luprintan TX 4493 (= Anthraquinone-2-sulfonic acid sodium salt) was tolerated without symptoms. None of the animals died. The LD50 was greater than 2000 mg/kg bw.

According to Commission Regulation (EU) 2016/863 of May 2016 acute toxicity testing by the dermal route (Annex VII, point 8.5.3., column 2) ‘does not need to be conducted if the substance does not meet the criteria for classification as acute toxicity or STOT SE by the oral route and no systemic effects have been observed in in vivo studies with dermal exposure’. The registered substance conforms with the requirements given above. Therefore, it can be concluded for acute dermal toxicity that the available information is conclusive for non-classification.  

Justification for classification or non-classification

In the valid oral toxicity study the LD50 was greater than 2000 mg/kg bw (discriminating dose).

According to Commission Regulation (EU) 2016/863 of May 2016 acute toxicity testing by the dermal route (Annex VII, point 8.5.3., column 2) ‘does not need to be conducted if the substance does not meet the criteria for classification as acute toxicity or STOT SE by the oral route and no systemic effects have been observed in in vivo studies with dermal exposure’. The registered substance conforms with the requirements given above. Therefore, it can be concluded for acute dermal toxicity that the available information is conclusive for non-classification.  

According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification for acute toxicity is therefore not justified.